| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IFNGR2 |
| Uniprot No | P38484 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-337aa |
| 氨基酸序列 | MRPTLLWSLLLLLGVFAAAAAAPPDPLSQLPAPQHPKIRLYNAEQVLSWEPVALSNSTRPVVYQVQFKYTDSKWFTADIMSIGVNCTQITATECDFTAASPSAGFPMDFNVTLRLRAELGALHSAWVTMPWFQHYRNVTVGPPENIEVTPGEGSLIIRFSSPFDIADTSTAFFCYYVHYWEKGGIQQVKGPFRSNSISLDNLKPSRVYCLQVQAQLLWNKSNIFRVGHLSNISCYETMADASTELQQVILISVGTFSLLSVLAGACFFLVLKYRGLIKYWFHTPPSIPLQIEEYLKDPTQPILEALDKDSSPKDDVWDSVSIISFPEKEQEDVLQTL |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IFNGR2重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**：*Structural and functional analysis of the human IFNGR2 receptor subunit using recombinant protein expression*
**作者**：Smith J, et al.
**摘要**：通过大肠杆菌表达系统成功制备重组人IFNGR2胞外段蛋白，解析其晶体结构，揭示其与IFN-γ及JAK激酶的结合界面，为免疫信号通路研究提供结构基础。
---
2. **文献名称**：*Recombinant IFNGR2 rescues STAT1 phosphorylation in IFNGR2-deficient cells*
**作者**：Lee S, et al.
**摘要**：构建重组IFNGR2蛋白并在IFNGR2缺陷的细胞系中验证功能，证明其恢复IFN-γ介导的STAT1磷酸化及抗病毒反应，支持其在遗传性免疫缺陷疾病治疗的潜力。
---
3. **文献名称**：*Expression and purification of bioactive murine IFNGR2 in mammalian cell systems*
**作者**：Garcia R, et al.
**摘要**：优化哺乳动物细胞表达体系生产具有生物活性的小鼠IFNGR2重组蛋白，证实其与IFN-γ受体复合物的组装能力，为动物模型中的免疫调节研究提供工具。
---
注：以上文献为模拟示例，实际引用时需根据具体研究补充真实文献信息。建议通过PubMed或Web of Science检索关键词“IFNGR2 recombinant protein”获取最新研究。
Interferon gamma receptor 2 (IFNGR2) is a critical component of the type II interferon (IFN-γ) receptor complex, playing an essential role in mediating immune responses. As a transmembrane protein, IFNGR2 pairs with IFNGR1 to form a functional receptor that binds IFN-γ, a cytokine central to innate and adaptive immunity. This interaction triggers JAK-STAT signaling pathways, leading to the activation of genes involved in antimicrobial defense, antigen presentation, and immune cell regulation. IFNGR2 is expressed on various immune cells, including macrophages, T cells, and natural killer cells, underscoring its broad role in host defense against intracellular pathogens, tumor surveillance, and inflammatory regulation.
Recombinant IFNGR2 protein is engineered to mimic the extracellular domain of the native receptor, often produced using mammalian expression systems or Escherichia coli to ensure proper folding and bioactivity. Its production enables researchers to study IFN-γ signaling mechanisms, receptor-ligand interactions, and immune modulation in vitro and in vivo. Clinically, defects in IFNGR2 are linked to Mendelian susceptibility to mycobacterial diseases (MSMD), a rare immunodeficiency disorder characterized by heightened vulnerability to weakly virulent mycobacteria. Recombinant IFNGR2 serves as a tool for investigating these genetic disorders and developing therapeutic strategies, such as receptor replacement therapies or targeted immunomodulators. Additionally, it has applications in cancer immunotherapy research, where IFN-γ pathways are manipulated to enhance antitumor responses. By facilitating precise control over IFN-γ signaling, recombinant IFNGR2 contributes to advancing both basic immunology and translational medicine.
×
